Product Information

PDS01ADC is a novel investigational tumor-targeting Interleukin 12 (IL-12) that enhances the proliferation, potency and longevity of T cells in the tumor microenvironment. Together with Versamune® based immunotherapies PDS01ADC works synergistically to promote a targeted T cell attack against cancers. PDS01ADC is given by a simple subcutaneous injection. Clinical data suggest the addition of PDS01ADC to Versamune® based immunotherapies demonstrate significant disease control by shrinking tumors and/or prolonging survival in recurrent/metastatic cancers with poor survival prognosis.

Disease state

Recurrent/metastatic cancer is cancer that has returned after initial treatment or has spread to another part of the body. The survival prognosis for these types of cancers is generally poor. Surgery, chemotherapy and radiation therapy are cornerstones of cancer treatment in the recurrent/metastatic setting. Complementary therapies delivered in combination are often needed to combat advanced, recurrent metastatic disease.

Development status

PDS01ADC is currently being evaluated in combination with Versamune® based immunotherapies in both preclinical and clinical programs for the treatment of various types of recurrent/metastatic cancers.

This website use cookies to facilitate the use of the website, improve its performance and security, personalize the proposed content.